GlassScriptPhysician profile
Thaer Almalouf
NPI 1083706279
$2,095.55
in general payments reported to CMS, 2019-2025
23 companies · $209 in 2025
The $209 reported for 2025 was more than what 75% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.57 · 2020: $165 · 2021: $383 · 2022: $482 · 2023: $317 · 2024: $514 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $298.22 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $265.80 | 2021-2024 | Qelbree, Qelbree |
| Cranial Technologies, INC | $236.92 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $208.02 | 2020-2025 | Bexsero, Pediarix, Penmenvy |
| Merck Sharp & Dohme LLC | $135.54 | 2020-2024 | Gardasil 9, M-M-R II, Vaxelis |
| Ironshore Pharmaceuticals INC. | $131.92 | 2022-2024 | Jornay Pm |
| Pfizer INC. | $121.61 | 2022-2025 | |
| Sanofi Pasteur INC. | $96.60 | 2021-2024 | |
| Neurelis, INC. | $93.81 | 2021-2022 | |
| Tris Pharma INC | $75.49 | 2020-2021 | |
| Corium, LLC | $61.44 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $58.43 | 2020-2022 | |
| Seqirus USA INC | $53.20 | 2022-2024 | Flucelvax Quadrivalent, Flucelvax |
| Teva Pharmaceuticals USA, INC. | $40.93 | 2025 | Uzedy |
| Ultragenyx Pharmaceutical INC. | $36.73 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $34.78 | 2024 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.72 | 2024 | Caplyta |
| Sobi, INC | $24.87 | 2019-2021 | |
| Alkermes, INC. | $23.37 | 2024 | Aristada, Lybalvi |
| Acadia Pharmaceuticals INC | $21.76 | 2025 | Daybue |
| Verrica Pharmaceuticals INC. | $18.19 | 2025 | Ycanth |
| Biogen, INC. | $17.73 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaer Almalouf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.